SHARONBIO

The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated March 17 2015 that The Board of Directors at their meeting held on March 17, 2015 has decided to go with the restructuring of the debts of the company. On basis of above the Company is required to clarify following: a) Details and reasons for restructuring; b) Quantitative and/ or qualitative effect of restructuring; c) Details of benefit, if any, to the promoter/promoter group/group companies from such proposed restructuring; d) Brief details of change in shareholding pattern (if

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors at their meeting held on March 17, 2015 has decided to go with the restructuring of the debts of the company.

Sharon Bio-Medicine Limited has informed the Exchange that the Company has received the certification for the approval of Good Manufacturing Practices (GMP) for both, Capsules and Tablets from United Kingdom - Medical & Health Care Product Regulatory Agency (UKMHRA) for its expanded area of Formulation and Tablets unit located at Selaqui, Uttarakhand. In the view of the above it should be noted that after the expansion the production capacity of the Compay's Formulation and Tablets plant located at Selaqui, Uttarakhand has been doubled in the term of production.

Sharon Bio-Medicine Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Dec-2014.

Sharon Bio-Medicine Limited has informed the Exchange that the Trading Window will be closed from February 3, 2015 to February 16, 2015 (both days inclusive).

Sharon Bio-Medicine Limited has informed the Exchange that CS Ms. Archana Hemant Andhare, has resigned as a Company Secretary as well as Compliance Officer of the Company w.e.f February 2, 2015 and Mr. Viral Dilip Vora has been appointed as a Company Secretary & Compliance Officer w.e.f February 2, 2015.

Sharon Bio-Medicine Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the December 17, 2014 as per clause 35A of Listing agreement.

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of the proceeding of the Annual General Meeting of the Company held on December 17, 2014.

Sharon Bio-Medicine Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from December 14, 2014 to December 17, 2014 for the purpose of Annual General Meeting to be held on December 17, 2014 and for ascertaining eligibility of the members for entitlement of final dividend.

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on November 21, 2014 has resolved and recommended final dividend @ 18% which amounts to Rs. 0.36/- per equity share of Rs. 2 each for the Financial Year ended June 30, 2014.

Sharon Bio-Medicine Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Sharon Bio-Medicine Limited has informed the Exchange that in terms of Code of conduct adopted by the Company under Regulation 12 of SEBI (Prohibition of Insider Trading) Regulation, 1992 and with reference to circular letter dated February 03, 2014 the Trading Window will be closed during the mentioned period for the corporate event : Window closure period : November 10, 2014 to November 14, 2014. Further it is informed that the Trading Window will open on November 15, 2014.

Ramco Properties pvt ltd has submitted to the Exchange vide letter dated October 21, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Revon Consultancy & Management Services Pvt Ltd has submitted to the Exchange vide letter dated October 21, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Venus Global Management & Consultancy Services pvt Ltd has submitted to the Exchange vide letter dated October 21, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bagulvani General Trading Pvt Ltd has submitted to the Exchange vide letter dated vide letter dated October 21, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Savita Gowda has submitted to the Exchange vide letter dated october 21, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Lalit Misra has submitted to the Exchange vide letter dated October 21, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Mohan Kala has submitted to the Exchange vide letter dated October 21, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on October 20 2014 has resolved and allotted 1,61,11,000 Warrants to the Promoter group on Preferential basis in compliance of SEBI (Issue of Capital and Disclosure Requirements) Regultions, 2009.

Sharon Bio-Medicine Limited has informed the Exchange regarding United Kingdom - Medicine & Health Care Product Regulatory Agency (UKMHRA) inspection conducted for Good Manufacturing Practices (GMP) for Company's recently Expanded Formulation Plant area located a Uttarakhand.

Sharon Bio-Medicine Limited has informed the Exchange that CS Samsad Alam Khan, has resigned as a Company Secretary as well as Compliance Officer of the Company w.e.f. October 10, 2014 and Ms. Archana Hemant Andhare has been appointed as a Company Secretary & Compliance Officer w.e.f. October 10, 2014.

Sharon Bio-Medicine Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-Jun-2014.

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of Result of Postal Ballot.

Sharon Bio-Medicine Limited has informed the Exchange regardiing the Outcome of Board Meeting of the Company.

Sharon Bio-Medicine Limited has informed the Exchange that one of the Company's unit located at Plot No- V-10, MIDC, Taloja, near Navi Mumbai Dist. Raigad, Maharashtra has been allotted Good Laboratory Practice Certificate which is on same line as Organization for Economic Co-operation & Development Certificate (OECD). With this Sharon can do Toxicity & Mutagenicity Studies and Analytical & Clinical Chemistry Testing. This will help Sharon to help big Pharma, Chemical & Agro companies to do research in their fields. Sharon will do the studies and testing in its laboratory for the companies all

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of Postal Ballot Notice approved by the Board for dispatch to Members of the Company for consiering issue of warrants convertible into equity capital on preferential basis to Promoter Group.

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors have approved issue of upto 1,80,00,000 warrants, convertible into equity shares to Promoter Group at a price to be calculated as per SEBI ICDR regulations, subject to a minimum price of Rs. 45 per warrant/ share ( Rs 2 towards face value and balance towards premium), subject to the consent of the Members of the Company to be obtained through Postal Ballot. Board approved the Postal Ballot notice to be sent to the Members.

Sharon Bio-Medicine Limited has informed the Exchange that "A fire has erupted in one of our API and Intermediate Plant located at Plot no W-34 & W-34/1, MIDC, Taloja Dist. Raigad, Maharashtra. The incident took place today as on June 03, 2014. No Human loss has been reported except for the Stock, Material and Capital loss. All the Stock, Material and Capital Assets have been adequately insured. The Company has also taken the Loss of Profit policy on this plant".

Sharon Bio-Medicine Limited has informed the Exchange regarding European Directorate for the Quality of Medicine & Healthcare (EDOM) approval for Plant Located at Plot No. L-6, MIDC, Taloja.

Sharon Bio-Medicine Limited has informed the Exchange that "Board of Directors has appointed Mr. Asif Rangwala as additional director of the company in the meeting held on May 15,2014. He will hold office as Independent Director till next Annual General Meeting of the company. Also the Board Of Directors has accepted resignation of Mr. Vivekanand Badoni & Mr Sanjay Shah as Independent Director with immediate effect & that they have resigned on personal grounds."

Sharon Bio-Medicine Limited has submitted to the exchange the standalone financial results for the period ended 31-Mar-2014.

Sharon Bio-Medicine Limited has informed the Exchange that Sharon has completed expansion in its 3 manufacturing facilities. The total investment in expansion has been incurred to the tune nearly Rs. 125 Crores. In Dehradun Formulation plant, the expanded expenditure has been app. Rs 85/- Crores whereas capacity ofthe plant has been increased more than double. Similarly, other plants' capacity has been added between 30% to 50%. The commercial production in Sharon two expanded plants at Taloja near Navi Mumbai have already been started and Dehradun Formulation expanded facility will start produ

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of minutes of Extra-Ordinary General Meeting held on February 08, 2014.

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 24, 2014, has resolved the following: 1. Allotment of 52784500 bonus equity shares of Rs. 2/- each. 2. Severally authorizing Ms. Savita Gowda, Managing Director of the Company and Mr. Mohan Kala, Director of the Company, to do all the acts and deeds in the above regard. 3. Authority to Share Transfer Agents of the Company, Link Intime India Pvt. Ltd. to issue share certificates.

Sharon Bio-Medicine Limited has informed the Exchange that the Company has fixed Record Date as February 21, 2014 for the purpose of Splitting / Sub-Division of each Equity Share of Face Value of Rs.10/- each into Five Equity Shares of Face value of Rs.2/- each and Issue of Fully Paid-up Bonus Shares in the ratio of 1:1 i.e., One Equity Share for every One Equity Share held on the record date.

Sharon Bio-Medicine Limited has submitted to the exchange the standalone financial results for the period ended 31-dec-2013.

Sharon Bio-Medicine Limited has informed the Exchange regarding a brief proceedings of the Extra Ordinary General Meeting held on February 08, 2014.

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of notice of Extra-Ordinary General Meeting of the Company to be held on February 08, 2014.

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on January 14, 2014, has resolved the following, subject to the approval of the Members: (1) Increase in Authorised Share Capital from Rs. 20,25,00,000/- (Rupees Twenty Crores Twenty-Five Lakhs Only) to Rs. 35,00,00,000/- (Rupees Thirty Five Crores Only). (2) The sub-division of Equity Shares of face value of Rs. 10/- each to Rs. 2/- each. (3) Issuance of Bonus Equity Shares in the Ratio of 1:1. (4) Altering the Clauses in the Memorandum of Association and Articles of Associatio

Sharon Bio-Medicine Limited has informed the Exchange vide letter dated December 17, 2013 regarding "U.K. Medicines & Health Care Product Regulatory Agency (MHRA) approval (GMP Certificate) of our Dehradun Formulation Plant".

Sharon Bio-Medicine Limited has submitted to the Exchange a copy of Proceeding of the Annual General Meeting of the Company held on December 09, 2013.

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on November 26, 2013, has resolved the following: (a) The old Bonds of USD $ 16.5 Million has been extended for further period of 5 Five Years and also resolved to issue the new Bonds USD $ 8.046 Million which shall be issued in lieu of interest accrued on the old bonds. The floor price of new bonds is Rupees 288.49, the conversion price of new bonds shall not be below the floor price.

Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at the Meeting held on November 14, 2013 has recommended dividend of Rs.1.50/- per share on 10556900 equity shares of Rs.10/- each fully paid up for the year ended 2012-13, subject to approval of the members at the ensuing Annual General Meeting.

Sharon Bio-Medicine Limited has informed the Exchange that the dividend shall be paid on January 06, 2014.

Sharon Bio-Medicine Limited has informed the Exchange that the Company has fixed Book Closure from December 5, 2013 to December 9, 2013 for the purpose of ascertaining eligibility of the members for entitlement of final dividend. Further, the Annual General Meeting of the Company is scheduled to be held on December 09, 2013.

Sharon Bio-Medicine Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2013.

Savita Gowda has submitted to the Exchange, vide letter dated October 28, 2013 a copy of disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Savita Gowda has submitted to the Exchange vide letter dated October 28, 2013 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sharon Bio-Medicine Limited has informed the Exchange that : 1.Mr. Drunal Shah, has resigned as a Director of the Company with effect from September 01, 2013. 2. Mr. Madhav Manohar Sapre is appointed as the Additional Director w.e.f. September 01, 2013.